Compugen Ltd.

CGEN | NASDAQ | 0 Followers
$1.37 +4.57% $0.06
Follow
Loading...

Profile

Compugen Ltd. (CGEN) is an Israeli biotechnology company focused on researching and developing new drugs and therapies for the treatment of oncology and immune-related diseases. The company utilizes advanced bioinformatics, artificial intelligence, and predictive genomics analysis to identify new drug targets and develop biologically active molecules. Compugen is focused on discovering innovative immunotherapeutic drugs that enhance immune responses against cancer and autoimmune diseases. The company also collaborates with pharmaceutical companies for the development and commercialization of its therapeutic products. Compugen has a broad portfolio of patented technologies and drug candidates that are under development and testing. It is recognized for its expertise in bioinformatics and immuno-oncology. Compugen Ltd. (CGEN) shares may represent an attractive investment opportunity for investors monitoring the biotechnology sector and seeking investments in a company with innovative research methods and potential in the field of oncology and immune-related diseases.

Feed

There are no posts to show right now.
Don't have an account? Join us

Log in to Bulios


Or use email and password
Already a member? Log in

Create Bulios profile

Continue with

Or use email and password
You can use lowercase letters, numbers, and underscores

Why Bulios?

One of the fastest growing investor communities in Europe

Comprehensive data on thousands of stocks from around the world

Current information from global markets and individual companies

Education and exchange of investment experience among investors

Fair prices, portfolio tracker, stock screener and other tools

Menu StockBot
Tracker
Upgrade